ArticleAnnals of medicine2025
ACT001 alleviates MASLD through gut microbiota-bile acid-FXR axis in mice.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Water extract of Artemisia capillaris alleviates fatty liver hemorrhagic syndrome in laying hens by modulating the gut microbiota-bile acid axis.Poultry science · 2026Article
- The Effect of Pediococcus Lactis and Postbiotics on Gut Health and Intestinal Metabolic Profiles.Nutrients · 2026Article
- Association between oral microbiome alpha and beta diversity and MASLD risk: a large-scale, population-based retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveACT001 is a novel sesquiterpene lactone derivative with noteworthy antineoplastic and anti-inflammatory properties. This study aimed to investigate the efficacy of ACT001 against metabolic dysfunction associated steatotic liver disease (MASLD) pathogenesis in two established murine models, and to elucidate its regulatory role in the gut microbiota-bile acid-FXR axis. MATERIALS AND
methodsA high-fat diet (HFD) and a methionine-choline-deficient (MCD) diet induced two MASLD models in C57BL/6J mice. Histological analysis was performed, biochemical indices were measured, and the expression of tight junctions and farnesoid X receptor (FXR)-related pathways was detected. Gut microbiota was assessed by 16S rDNA sequencing, while bile acids (BAs) in fecal samples were analyzed using UPLC/MS-MS.
resultsACT001 decreased liver injury, alleviated hepatic lipid accumulation, and restored intestinal barrier integrity. Furthermore, 16S rDNA illustrated that ACT001 could partially rebalance intestinal dysbacteriosis and upregulate the relative abundance of various bacteria, especially
conclusionACT001 exerted a multifactorial therapeutic effect on MASLD, potentially linked to the regulation of the gut microbiota-BAs-FXR axis. Thus, it has the potential to be an effective treatment for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.